logo
Doctor who failed to spot girl, 13, was suffering from sepsis and died days later will face no disciplinary sanction

Doctor who failed to spot girl, 13, was suffering from sepsis and died days later will face no disciplinary sanction

Daily Mail​a day ago

A senior doctor who failed to spot that a 13-year-old girl was suffering from sepsis before she died will face no disciplinary sanctions for failings in his care.
Professor Richard Thompson did not refer Martha Mills to intensive care at King's College Hospital in London despite her displaying several high-risk indicators of the life-threatening condition.
The on-call consultant also chose not to return to the hospital to assess her in person as her condition deteriorated.
A Medical Practitioners Tribunal Service (MPTS) panel sitting in Manchester had ruled those omissions were misconduct, which they described as 'particularly grave', and found his fitness to practise was impaired.
But today the tribunal decided there were 'exceptional circumstances' which justified taking no further action against the world-renowned paediatric liver specialist.
Martha had been an inpatient on the hospital's Rays of Sunshine Ward after she suffered a serious injury to her pancreas when she slipped while riding a bike on a family holiday in Wales in July 2021.
Weeks later she experienced a fever and increased heart rate, followed by more spikes in her temperature before the consultant hepatologist saw Martha on his morning ward round on Sunday August 29.
Prof Thompson left the hospital at 3pm, but was phoned at home two hours later by a trainee doctor, who gave an update on Martha's condition.
Medical records showed she had deteriorated over the course of the afternoon, and into the early evening, with a drop in her blood pressure, the appearance of a new rash and increases in heart rate, respiratory rate and body temperature.
Tribunal chairman Robin Ince noted that by 5pm there were 'several high-risk indicators' as set out in the Nice guidelines relating to sepsis.
The duty registrar called Prof Thompson again at 8.30pm because of ongoing concerns over Martha's fever, but she was kept on the ward despite the continued presence of moderate to high-risk indicators and the absence of meaningful clinical improvement.
Martha collapsed on August 30 and was moved to intensive care before she was transferred to London's Great Ormond Street Hospital, where she died in the early hours of August 31.
Announcing its conclusions on Wednesday, Mr Ince said: 'Professor Thompson has done everything possible to address his failings.
'The tribunal considered that the best way to repair any harm caused by his failings would be for him to continue to provide his specialist expertise at home and abroad.
'To now - some four years after the index event - remove Professor Thompson from practice, even for a short period of time, for one single lapse of judgment in an otherwise exemplary career would, in the tribunal's view, be akin to punishment which is not the role of the MPTS.'
Among the 'exceptional circumstances' cited were that there was no allegation or evidence that Prof Thompson either caused or contributed to Martha's death.
There were also systemic failings regarding how the ward functioned at the time with regard to referrals to the paediatric intensive care unit, said the tribunal.
Mr Ince said: 'A sufficiently clear message has already been sent to the profession and to the public - that even such an experienced doctor as Professor Thompson could still make serious errors of clinical judgment for which he will be called to account.
'The public would be aware that this finding would remain a stain on Professor Thompson's reputation for the rest of his life.'
At a 2022 inquest into her death, a coroner ruled that Martha would most likely have survived if doctors had identified the warning signs and transferred her to intensive care earlier.
Martha's mother, Merope Mills, said she and her husband, Paul Laity, raised concerns about Martha's deteriorating health a number of times but these were not acted on.
The couple later successfully campaigned for Martha's Rule to give patients, families and carers the chance to easily request a second opinion from a senior doctor in the same hospital in the event of a suspected deterioration or serious concern.
Giving evidence, Prof Thompson told the MPTS hearing that he no longer provided in-patient care because he began to 'doubt my own judgment' after the tragic events.
He said he felt 'deep remorse' for Martha's death but did not believe he made any errors in her case, as he denied all the allegations brought by the General Medical Council (GMC).
The tribunal heard he had since completed a training course relating to the management of sepsis and a deteriorating child in paediatric care.
His barrister, Ben Rich, said Prof Thompson has been a dedicated doctor and specialist for nearly 40 years and had never previously been investigated by a regulator.
He said he had a reputation as a 'hard-working and outstanding clinician and researcher, who has an international reputation as one of the leading paediatric liver specialists in the world'.
Mr Rich urged the tribunal members to impose an order of conditions involving supervision on Prof Thompson's registration, but the panel disagreed and said such a measure would be 'unnecessary and artificial', as they opted to take no further action.
Christopher Rose, for the GMC, said that Prof Thompson should be suspended to send a message to the wider public and the wider profession, given the seriousness of the failings found.
The tribunal had cleared Prof Thompson of the GMC's claims that he gave 'outdated, misleading' information on Martha's condition to a consultant colleague in the intensive care unit, and that he failed to mention her rash.
In ruling his fitness to practise was impaired, Mr Ince said: 'There had been a significant potential risk of harm to Martha and it was appropriate to send a message to the profession as to the importance of following the basic and fundamental principles as set out in good medical practice so as to ensure that the potential risks of an adverse outcome are always taken into account.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside
NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside

The Independent

time42 minutes ago

  • The Independent

NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside

Blood cancer patients in England are set to be among the first in the world to access a pioneering "Trojan horse" treatment, health officials have announced. The targeted therapy, belantamab mafodotin, also known as Blenrep, has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, according to studies. Approximately 1,500 patients annually with multiple myeloma, an incurable bone marrow cancer, are expected to benefit from this new treatment. The National Institute for Health and Care Excellence (Nice) has approved Blenrep, manufactured by GlaxoSmithKline, for use within the NHS. NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be available to patients whose cancer has advanced or has not responded to initial treatments. Administered as an infusion every three weeks alongside other cancer drugs, this antibody drug targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'

Sickle cell patients to have quicker and more accessible treatment in England
Sickle cell patients to have quicker and more accessible treatment in England

The Guardian

timean hour ago

  • The Guardian

Sickle cell patients to have quicker and more accessible treatment in England

People living with sickle cell disease in England are to benefit from quicker and more accessible treatment due to a £9m investment, the government has announced. Apheresis services, which are a type of treatment that removes harmful components from a patient's blood, are to improve across England through the funding of more specialist treatment centres. The funding will ensure the wider availability of machines that remove a patient's sickled red blood cells and replace them with healthy donor cells. More than 20 NHS trusts currently offer Spectra Optia technology, a treatment more effective than blood transfusions and having been shown to be highly effective in reducing complications such as iron overload. The investment could save the NHS up to £12.9m every year thanks to a reduction in time spent in hospital for patients and the reduced need for other treatments, according to the government. Sickle cell disease primarily affects people from an African-Caribbean background. In England, about 17,000 people are living with the disease, an inherited blood disorder, with 250 new cases a year. Wes Streeting, the health and social care secretary, said: 'People living with rare conditions like sickle cell disease face immense everyday challenges, and can sometimes struggle to get the specialised care they need. 'To make our health service fit for the future, we have to harness the power of new technologies, and these machines provide a shining example of how our government is starting to make huge advancements in digital healthcare. 'Through our plan for change, this government will be the one that removes the barriers to getting the latest and best tech to our NHS frontline, so patients can access the best care available, closer to home.' Prof Bola Owolabi, the director of healthcare inequalities at NHS England, said: 'This is great news for people living with sickle cell disease – a condition that disproportionately affects Black African and Black Caribbean communities. 'Sickle cell patients have needed new treatment options for decades and this additional funding will provide greater access to this life-changing technology which has the potential to significantly improve patients' quality of life.' Owolabi added that sickle cell care in England continued to be among the best in the world, with England the first country to introduce a groundbreaking gene-editing therapy, which offers a functional cure to the disease. Sign up to First Edition Our morning email breaks down the key stories of the day, telling you what's happening and why it matters after newsletter promotion 'Alongside this important step, the recent approval of a new gene-editing therapy for patients with severe sickle cell disease showcases the NHS's clear commitment to improving outcomes for the 17,000 people living with the condition in England,' Owolabi said. John James, the chief executive of the Sickle Cell Society, said: 'We are delighted to see the arrival of this long-overdue funding, which will improve access to vital treatment for people living with sickle cell disorder and their families. 'This announcement follows years of collaboration between the Sickle Cell Society and the NHS, and we're pleased that this investment will help make access to care fairer, more consistent, and far less stressful for many individuals.'

‘Trigger toolkit' for museums comes with its own warning
‘Trigger toolkit' for museums comes with its own warning

Times

timean hour ago

  • Times

‘Trigger toolkit' for museums comes with its own warning

A guide that advises prominent museums on how to deal with sensitive topics including divorce, poverty and violence put a content warning on its own 27-page 'trigger toolkit'. The booklet was released by Museum Development North, which is a partnership funded by Arts Council England between York Museums Trust, the Manchester Museums Partnership, Cumbria Museum Consortium and North East Museums. The aim of the booklet is to 'support organisations working across the sector to take a practical approach to preventing, responding to and managing a triggering event within a training session'. The 27-page guide, called 'Trigger Toolkit', advises leaders in the heritage sector on how to prepare training content that will reduce the likelihood of staff being 'triggered' during their work with collections or artefacts. • Chocolat author Joanne Harris adds trigger warnings to her books Due to 'sensitive' topics, the training guide has two pages of warnings in large red type that states: 'The following two pages contain potentially triggering content.' People working in the heritage sector are exposed to collections that include 'racist and intolerant artefacts', which could bring back childhood trauma and prompt memories of 'offensive language and name calling', the toolkit states. Included among the more than 40 topics that could affect museum staff were death, divorce, childbirth, debt, ­violence, politics, classism and warfare. Gambling, hateful language, the climate emergency, disease, the criminal justice system, policing, and natural disasters were among other examples of 'possible triggering topics' included in the toolkit. The document cites 2022 research that describes a trigger as a 're-experiencing of ­unpleasant post traumatic stress disorder symptoms such as intrusive thoughts being evoked by the ­exposure to materials which spark traumatic memories'. Liz Main, a mental health policy ­expert who has studied trigger warnings, said: 'On balance I think trigger warnings can be a good thing as they can stop someone from seeing something that may upset them. However, the fact that the booklet is about trigger warnings would indicate to staff that there may be emotionally distressing content in there.' The toolkit was developed by Inclusive Boards in partnership with Museum Development Yorkshire. The guide states: 'Many artefacts and conversation subject matters relevant to the heritage sector speak to a time in which intolerant, discriminatory, and offensive attitudes and behaviours were significantly more prevalent than they are today … It is important that in navigating this history organisations ensure that equality, diversity and inclusion is a priority.' Museum Development North had no further comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store